Q3 FY2026 · ended Sep 30, 2026 · Revenue $275.36M, +27.0% YoY · Filed Nov 4, 2026
Caris Life Sciences, Inc. (CAI) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $275.4 million and net income of $15.2 million. Free cash flow was -$39.7 million. As of Sep 30, 2026 it held $102.1 million in cash and investments and $463.0 million in total debt.
Revenue
$275.36M
+27.0% vs year-ago quarter
Net income
$15.25M
-37.3% vs year-ago quarter
Operating cash flow
$-22.25M
-135.6% vs year-ago quarter
Free cash flow
$-39.72M
-171.8% vs year-ago quarter
EPS
$0.05
-37.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
286.78M
+1.6% vs year-ago quarter
Net cash
$-360.96M
Q3 FY2026
Operating margin
13.4%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- CAI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Irving, TX
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2019410
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $275.4M | $263.7M | $216.2M | $292.9M | $216.8M |
| Operating income | $19.3M | $26.9M | $5.3M | $88.4M | $32.6M |
| Net income | $15.2M | -$637,000 | -$510,000 | $82.0M | $24.3M |
| Diluted EPS | $0.05 | $0.00 | $0.00 | $0.29 | $0.08 |
| Operating cash flow | -$22.2M | $28.5M | $32.9M | $44.8M | $62.4M |
| Free cash flow | -$39.7M | -$3.9M | $22.5M | $39.7M | $55.3M |
| Total assets | $1.3B | $1.2B | $1.2B | $1.1B | $984.6M |
| Total liabilities | $616.1M | $637.9M | $568.9M | $548.4M | $506.2M |
| Stockholders' equity | $639.5M | $591.7M | $593.5M | $577.3M | $478.4M |
| Cash and investments | $102.1M | $102.2M | $822.2M | $798.6M | $755.5M |
| Total debt | $463.0M | $452.4M | $431.0M | $428.2M | $426.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
All 134 Caris Life Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.